Going Viral

Earning CPD by listening to Healthed podcasts is simple. Each episode is eligible for Educational Activities CPD.

Filter results

0.5 EA, 0.5 RP

If a new variant is more pathogenic then we are effectively back to square one and yet we have no strategy for this

0.5 EA, 0.5 RP

Booster advice- get it every 6 months, the bivalent vaccines in practice

0.5 EA, 0.5 RP

Zinc, Selenium, Melatonin, and Vitamin D supplements are useful adjuncts in the early stages of COVID-19 infection

0.5 EA, 0.5 RP

COVID – 5th dose, flu – concurrent annual booster, many recrudescent diseases

0.5 EA, 0.5 RP

How healthy young people will derive little benefit from a fourth or fifth dose of vaccine, and how we should keep them for the vulnerable population, and China's response to the COVID surge being of global interest and concern

0.5 EA, 0.5 RP

The pros and cons of a 5th jab for health workers, whether we have reached the end of the road with mRNA-based vaccines, cutting through the subvariant hype, new vaccines on the horizon, and the 2023 forecast - does ATAGI need a rethink?

0.5 EA, 0.5 RP

The 4th wave, booster advice, Christmas forecasting - will the current wave be over soon?, the scale and impact of the anticipated long COVID crisis

0.5 EA, 0.5 RP

Entering a new wave driven by a soup of Omicron sub-variants, where more than 5 million Australians eligible for boosters have not received them, and how we must encourage patients to get their boosters, with the bivalent vaccines being more effective

0.5 EA, 0.5 RP

The new COVID wave comprising of BQ1, XBB and other variants, and what our frontline response should look like, whether a fifth booster is worth having, children's vaccination developments and an update on the antivirals

0.5 EA, 0.5 RP

How resources are being diverted to COVID-19, and how they have been affecting Tuberculosis resources, knowing when to suspect and diagnose active Tuberculosis and how to manage the patient

0.5 EA, 0.5 RP

The bivalent vaccines, the new variant alert for Ba.2.75 and Ba.4.6, and herd immunity predictions and implications

0.5 EA, 0.5 RP

Despite a panoramic study suggesting a lower effect, Lagevrio has a useful impact on hospitalisations, deaths and shorter recovery time. Additionally COVID trials becoming more difficult to run because so many people have either been vaccinated and / or exposed

If a new variant is more pathogenic then we are effectively back to square one and yet we have no strategy for this

Booster advice- get it every 6 months, the bivalent vaccines in practice

Zinc, Selenium, Melatonin, and Vitamin D supplements are useful adjuncts in the early stages of COVID-19 infection

COVID – 5th dose, flu – concurrent annual booster, many recrudescent diseases

How healthy young people will derive little benefit from a fourth or fifth dose of vaccine, and how we should keep them for the vulnerable population, and China's response to the COVID surge being of global interest and concern

The pros and cons of a 5th jab for health workers, whether we have reached the end of the road with mRNA-based vaccines, cutting through the subvariant hype, new vaccines on the horizon, and the 2023 forecast - does ATAGI need a rethink?

The 4th wave, booster advice, Christmas forecasting - will the current wave be over soon?, the scale and impact of the anticipated long COVID crisis

Entering a new wave driven by a soup of Omicron sub-variants, where more than 5 million Australians eligible for boosters have not received them, and how we must encourage patients to get their boosters, with the bivalent vaccines being more effective

The new COVID wave comprising of BQ1, XBB and other variants, and what our frontline response should look like, whether a fifth booster is worth having, children's vaccination developments and an update on the antivirals

How resources are being diverted to COVID-19, and how they have been affecting Tuberculosis resources, knowing when to suspect and diagnose active Tuberculosis and how to manage the patient

The bivalent vaccines, the new variant alert for Ba.2.75 and Ba.4.6, and herd immunity predictions and implications

Despite a panoramic study suggesting a lower effect, Lagevrio has a useful impact on hospitalisations, deaths and shorter recovery time. Additionally COVID trials becoming more difficult to run because so many people have either been vaccinated and / or exposed

Upcoming Healthed Webcast

Abnormal Liver Function Test Interpretation

Tuesday 31st March, 7pm - 9pm AEDT

Speaker

Dr Emily Nash

Gastroenterologist and Hepatologist; Chris O'Brien Lifehouse; Clinical Associate Lecturer, University of Sydney

Join Dr Emily Nash for their lecture where they will offer a framework to interpret abnormal LFTS and suggest diagnostic algorithms to help determine the most appropriate next step.